| 1.14 0.01 (0.89%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.45  |
1-year : | 1.63 |
| Resists | First : | 1.24 |
Second : | 1.39 |
| Pivot price | 1.12 |
|||
| Supports | First : | 1 |
Second : | 0.83 |
| MAs | MA(5) : | 1.13 |
MA(20) : | 1.12 |
| MA(100) : | 1.34 |
MA(250) : | 1.13 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 55.8 |
D(3) : | 53.3 |
| RSI | RSI(14): 50.7 |
|||
| 52-week | High : | 4.75 | Low : | 0.24 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ FEMY ] has closed below upper band by 39.2%. Bollinger Bands are 73.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.29 - 1.3 | 1.3 - 1.3 |
| Low: | 0.99 - 0.99 | 0.99 - 1 |
| Close: | 1.13 - 1.14 | 1.14 - 1.15 |
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Tue, 16 Jul 2024
Femasys Inc. (NASDAQ:FEMY) Sees Significant Increase in Short Interest - American Banking and Market News
Sun, 14 Jul 2024
Femasys Inc. (NASDAQ:FEMY) Short Interest Update - Defense World
Fri, 05 Jul 2024
Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now - Simply Wall St
Thu, 27 Jun 2024
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual ... - WDRB
Thu, 09 May 2024
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update - GlobeNewswire
Thu, 02 May 2024
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 1.999e+007 (%) |
| Held by Institutions | 7.6 (%) |
| Shares Short | 835 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.451e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 277 % |
| Return on Equity (ttm) | -48.8 % |
| Qtrly Rev. Growth | 1.05e+006 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.07 |
| EBITDA (p.s.) | -0.69 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 15.98 |
| Price to Cash Flow | -4.5 |
| Dividend | 0 |
| Forward Dividend | 1.01e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|